From: Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality
Matching Variable | Age < 65 years N = 304 | Age ≥ 65 years N = 71 | P-value | Standardized Mean Difference |
---|---|---|---|---|
TRT^{a} (N, %) | 132 (43.4%) | 33 (46.5%) | 0.738 | 0.061 |
Median First Testosterone, ng/dL (IQR) | 175 (145, 202) | 185 (161, 196) | 0.291 | 0.126 |
Median Second Testosterone, ng/dL (IQR) | 169 (139, 195) | 176 (141, 195) | 0.526 | 0.040 |
Median Income, United States Dollars (IQR) | 54,440 (44,810, 71,425) | 61,069 (45,653, 66,588) | 0.538 | 0.071 |
Median Age, years (IQR) | 54 (48, 59) | 69 (66, 74) | < 0.001 | 0.687 |
Diabetes (N, %) | 116 (38.2%) | 39 (54.9%) | 0.014 | 0.341 |
Tobacco Use (N, %) | 2 (0.1%) | 0 | 1 | 0.115 |
LDL > 130 mg/dL | 37 (12.2%) | 1 (1.4%) | 0.013 | 0.438 |
Median LDL, mg/dL (IQR) | 95 (74, 117) | 79 (59, 107) | 0.001 | 0.536 |
Hypertension (N, %) | 193 (63.5%) | 60 (84.5%) | 0.001 | 0.494 |
Statin (N, %) | 147 (48.4%) | 45 (63.4%) | 0.032 | 0.306 |
BMI ≥ 30 kg/m^{2} | 276 (90.8%) | 60 (84.5%) | 0.179 | 0.192 |
Median BMI, kg/m^{2}(IQR) | 36.3 (32.2, 41.0) | 34.1 (31.1, 37.9) | 0.004 | 0.323 |
Previous Cardiovascular Disease (N, %) | 35 (11.5%) | 34 (47.9%) | < 0.001 | 0.868 |
Charlson Comorbidity Index (N, %) | < 0.001 | 1.068 | ||
0 | 134 (44.1%) | 13 (18.3%) | ||
1 | 85 (28.0%) | 5 (7.0%) | ||
> 1 | 85 (28.0%) | 53 (74.6%) | ||
Composite Outcome (N, %) | 15 (4.9%) | 13 (18.3%) | ||
Myocardial Infarction (N, %) | 5 (1.6%) | 2 (2.8%) | ||
Stroke (N, %) | 8 (2.6%) | 8 (11.3%) | ||
Death (N, %) | 2 (0.7%) | 3 (4.2%) |